| Document Date: 2015-04-15 08:48:13
Open Document File Size: 3,27 MBShare Result on Facebook
City San Francisco / Hyderabad / / Company 3M Germany / Pfizer / New England Journal / Daiichi Sankyo / Bayer Global / Needham & Company / AstraZeneca / Baxter / / Country United States / / Currency USD / / Event Product Issues / FDA Phase / / Facility Filed Products Robust Pipeline of Drug Candidates Efficient R&D Organization / CA Headquarters / / IndustryTerm treatment for hemophilia / long-acting products / / MedicalCondition Treat Opioid-Induced Constipation / cancer / hemophilia A / Chronic / constipation / chronic / non-cancer pain / / Organization ROW / Drug Candidates Efficient R&D Organization / European Union / U.S. Securities and Exchange Commission / / Person Stephen Doberstein / Approval / Mayo Clin Proc / / Position Vice President & Chief Scientific Officer / Nurse / Physician / / Product Cipro / Once-Daily Oral Tablet / Q4 / movantik / response / Movantik™ / / PublishedMedium New England Journal of Medicine / / Technology Anti-Infectives / / URL www.movantik.com / /
SocialTag |
Needham & Company 2015 Healthcare Conference Stephen Doberstein, Ph.D. Senior Vice President & Chief Scientific Officer April 15, 2015